Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : XL-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : French Government
Deal Size : $2.7 million
Deal Type : Funding
Allogenica Wins €2.5M Grant for Universal CAR-T Therapy Advancement
Details : The funding will help accelerate the industrialization of Allogenica’s lead-candidate CAR-T, called the XL-001 for treating CD19-positive blood cancers.
Product Name : XL-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : XL-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : French Government
Deal Size : $2.7 million
Deal Type : Funding